A Significant Step Forward in ALS Treatment In a major development for the neuroscience community, Zhimeng Biopharma has officially announced the completion of patient enrollment for its investigational drug, CB03-154. This marks a pivotal milestone in the company’s ongoing Phase 2/3 clinical trial focused on treating Amyotrophic Lateral Sclerosis (ALS). Understanding the Clinical Trial ALS…